Last reviewed · How we verify
NCT04418817
Modulus in XLIF Study
trial in Degenerative Disc Disease in 36 participants. Completed in 31 January 2024.
31 January 2024
Quick facts
| Lead sponsor | NuVasive |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 36 |
| Start date | 22 March 2020 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 2 locations across United States |
Conditions studied
- Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
- Degenerative Spondylolisthesis — all drugs for Degenerative Spondylolisthesis →
- Degenerative Scoliosis — all drugs for Degenerative Scoliosis →
Sponsor
NuVasive — full company profile →
Who can join
18 and older, any sex, with Degenerative Disc Disease or Degenerative Spondylolisthesis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the safety and performance of the Modulus 3D-printed titanium interbody implant in patients undergoing thoracic and/or lumbar XLIF as measured by reported complications, radiographic outcomes, and patient-reported outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04418817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Degenerative Disc Disease
Currently open trials in the same condition.
- NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
- NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
- NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting
Other NuVasive trials
Trials by the same sponsor.
- NCT06741514 — A Study of Precice Intramedullary Limb Lengthening System (IMLL) Limb Lengthening Procedures · enrolling by invitation
- NCT05691231 — Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels · enrolling by invitation
- NCT05566704 — Retrospective Modulus ALIF Study · completed
- NCT05066711 — NuVasive® ACP System Study · enrolling by invitation
- NCT04980378 — Post Approval Study Protocol for the Two Level Simplify® Cervical Artificial Disc · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04418817 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NuVasive
- Last refreshed: 22 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04418817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing